To describe the patient response, including effects on disability and function, to eptinezumab in a real-world setting after 6 months of preventive migraine treatment.

 The anti-calcitonin gene-related peptide monoclonal antibody eptinezumab is approved for the prevention of migraine in adults. Evidence from post-marketing studies is needed to better understand how eptinezumab prevents migraine in the real-world setting.

This retrospective chart review examined data from adults who initiated preventive treatment and received at least 2 infusions of eptinezumab (100mg or 300mg) at headache clinics between April and October 2020. Demographic information, treatment history, migraine and headache frequency, disease characteristics, and disability assessment scores (e.g., Migraine Disability Assessment [MIDAS], Headache Impact Test [HIT-6]) were collected using standardized case-report forms completed by physicians. These report forms measured patient and clinician perspectives on eptinezumab treatment response.

This analysis includes data from 31 patients with migraine (mean age, 50.7 years; 100% white [27/27]; 81.5% female [22/27]; 93.5% chronic migraine [29/31]) had been collected across 8 sites. Relative to baseline, 6 months of preventive treatment with eptinezumab reduced mean monthly headache days (23.5 at baseline, 16.3 at Month 6), mean monthly migraine days (17.9 at baseline, 9.1 at Month 6), and patient-reported disability (50.0% [11/22] severe at baseline per MIDAS and/or HIT-6, 36.8% [7/19] severe at Month 6). Eptinezumab treatment was also associated with reduced acute headache medication use (16.7 mean acute medication days per month in the last 3 months prior to treatment and 8.3 at Month 6). Clinicians reported that treatment was well-tolerated (96.8%) and improved disability/function (77.4%) after 6 months of use.

Early clinical experience with eptinezumab and the magnitude of improvement is consistent with results reported in controlled clinical trials, with reductions in headache frequency and associated disability evident during the first 6 months of treatment.